Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA.
Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA.
Methods Mol Biol. 2024;2805:89-100. doi: 10.1007/978-1-0716-3854-5_5.
Engineered heart tissues (EHTs) have been shown to be a valuable platform for disease investigation and therapeutic testing by increasing human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) maturity and better recreating the native cardiac environment. The protocol detailed in this chapter describes the generation of miniaturized EHTs (mEHTs) incorporating hiPSC-CMs and human stromal cells in a fibrin hydrogel. This platform utilizes an array of silicone posts designed to fit in a standard 96-well tissue culture plate. Stromal cells and hiPSC-CMs are cast in a fibrin matrix suspended between two silicone posts, forming an mEHT that produces synchronous muscle contractions. The platform presented here has the potential to be used for high throughput characterization and screening of disease phenotypes and novel therapeutics through measurements of the myocardial function, including contractile force and calcium handling, and its compatibility with immunostaining.
工程心脏组织 (EHT) 通过提高人诱导多能干细胞衍生的心肌细胞 (hiPSC-CM) 的成熟度并更好地再现天然心脏环境,已被证明是一种用于疾病研究和治疗测试的有价值的平台。本章详细描述了在纤维蛋白水凝胶中生成包含 hiPSC-CM 和人基质细胞的微型 EHT (mEHT) 的方法。该平台利用了一系列设计用于适配标准 96 孔组织培养板的硅树脂柱。基质细胞和 hiPSC-CM 浇铸在纤维蛋白基质中,悬浮在两个硅树脂柱之间,形成一个 mEHT,可产生同步的肌肉收缩。这里介绍的平台具有通过测量心肌功能(包括收缩力和钙处理)以及与免疫染色的兼容性,对疾病表型和新型治疗药物进行高通量表征和筛选的潜力。